| Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection NJ Shah, G Al-Shbool, M Blackburn, M Cook, A Belouali, SV Liu, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 115 | 2019 |
| Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, ... Journal of Clinical Oncology 40 (21), 2333, 2022 | 100 | 2022 |
| Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer WJ Kelly, NJ Shah, DS Subramaniam Frontiers in oncology 8, 208, 2018 | 81 | 2018 |
| Salvage ipilimumab and nivolumab in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitors A Gul, TF Stewart, CM Mantia, NJ Shah, ES Gatof, Y Long, KD Allman, ... Journal of Clinical Oncology 38 (27), 3088, 2020 | 76 | 2020 |
| Product review on the Anti-PD-L1 antibody atezolizumab NJ Shah, WJ Kelly, SV Liu, K Choquette, A Spira Human vaccines & immunotherapeutics 14 (2), 269-276, 2018 | 66 | 2018 |
| Clinical characterization of colitis arising from anti-PD-1 based therapy DY Wang, MJ Mooradian, DW Kim, NJ Shah, SE Fenton, RM Conry, ... Oncoimmunology 8 (1), e1524695, 2019 | 50 | 2019 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 40 | 2021 |
| Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade J Beattie, H Rizvi, P Fuentes, J Luo, A Schoenfeld, IH Lin, M Postow, ... Journal for ImmunoTherapy of Cancer 9 (2), 2021 | 39 | 2021 |
| Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase 2 trial. CH Lee, MH Voss, MI Carlo, YB Chen, E Reznik, A Knezevic, ... Journal of Clinical Oncology 39 (15_suppl), 4509-4509, 2021 | 36 | 2021 |
| A case of checkpoint inhibitor-induced celiac disease D Alsaadi, NJ Shah, A Charabaty, MB Atkins Journal for immunotherapy of cancer 7, 1-5, 2019 | 28 | 2019 |
| Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing H Truong, R Sheikh, R Kotecha, Y Kemel, PA Reisz, AT Lenis, NN Mehta, ... European urology oncology 4 (6), 993-1000, 2021 | 20 | 2021 |
| Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era NJ Shah, SD Sura, R Shinde, J Shi, PK Singhal, NJ Robert, NJ Vogelzang, ... European Urology Open Science 49, 110-118, 2023 | 19 | 2023 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 16 | 2023 |
| Automated identification of patients with immune-related adverse events from clinical notes using word embedding and machine learning S Gupta, A Belouali, NJ Shah, MB Atkins, S Madhavan JCO Clinical Cancer Informatics 5, 541-549, 2021 | 14 | 2021 |
| Association between body mass index and immune-related adverse events (irAEs) among advanced-stage cancer patients receiving immune checkpoint inhibitors: a pan-cancer analysis D Zhang, NJ Shah, M Cook, M Blackburn, MT Serzan, S Advani, ... Cancers 13 (23), 6109, 2021 | 13 | 2021 |
| PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma GT Gibney, J Zaemes, S Shand, NJ Shah, D Swoboda, K Gardner, ... Journal for Immunotherapy of Cancer 9 (10), 2021 | 12 | 2021 |
| The impact of androgen deprivation therapy on COVID-19 illness in men with prostate cancer NJ Shah, VG Patel, X Zhong, L Pina, JE Hawley, E Lin, BA Gartrell, ... JNCI cancer spectrum 6 (3), pkac035, 2022 | 10 | 2022 |
| Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs). NJ Shah, BT Ma, WJ Kelly, A Belouali, MT Serzan, SO Gonzalez, B Colton, ... Journal of Clinical Oncology 36 (15_suppl), e15074-e15074, 2018 | 10 | 2018 |
| A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have … NJ Shah, K Beckermann, NJ Vogelzang, SS Mao, MC Ornstein, ... Journal of Clinical Oncology 40 (16_suppl), 4511-4511, 2022 | 9 | 2022 |
| A survey to identify determinants that influence self-perceived sensitive skin in a British population: clues to developing a reliable screening tool for sensitive skin N Fawkes, E Tselenti, N Shah, V Lappin, N Smith, A Narasimhan, ... Clinical, Cosmetic and Investigational Dermatology, 1201-1210, 2021 | 9 | 2021 |
